Drugs / CG-0255
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07619885 | Jun → Oct 2026 expected | acute coronary syndrome, acute myocardial infarction, peripheral arterial disease, stroke disorder | Shanghai CureGene Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CG-0255 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07619885 ↗ |
| Route | Intravenous | “0.05 mg/kg CG-0255 Besylate for IV infusion within 30 minutes on Day 1.” NCT07619885 ↗ |